Glen Harbor Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Glen Harbor Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$167K	Hold	3,454	–	–	﹤0.01%	1070
2019 Q2	$182K	Sell	3,454 -506	-13%	-$29.1K	﹤0.01%	1037
2019 Q1	$210K	Sell	3,960 -2,860	-42%	-$141K	﹤0.01%	982
2018 Q4	$280K	Buy	+6,820	New	+$256K	0.01%	839
2018 Q3	–	Sell	-968	Closed	-$44K	–	1299
2018 Q2	$44K	Buy	+968	New	+$44.1K	﹤0.01%	1225

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Glen Harbor Capital Management's GBT Position: Q3 2019 in Review

Glen Harbor Capital Management held its Global Blood Therapeutics, Inc. (GBT) position steady in Q3 2019 at 3,454 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #1070.

Glen Harbor Capital Management first reported a position in GBT in Q2 2018 and has held it in 5 quarters since. The position peaked at $280K in Q4 2018. 208 funds tracked by Wall St. Rank hold GBT as of Q3 2019.

Glen Harbor Capital Management held 3,454 shares of Global Blood Therapeutics, Inc. worth $167K as of Q3 2019.
Glen Harbor Capital Management left its Global Blood Therapeutics, Inc. share count unchanged in Q3 2019.
Global Blood Therapeutics, Inc. made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1070 holding.
Glen Harbor Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2018 and has held it in 5 quarters since.
Glen Harbor Capital Management's Global Blood Therapeutics, Inc. position peaked at $280K in Q4 2018.
208 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.